title: Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
abstract: BACKGROUND
  The aim of the present study was to analyze the expression of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including patients' survival time.
  
  
  METHODS
  Using real-time PCR, we detected the expression of EIF4G1 in normal nasopharyngeal tissues, immortalized nasopharyngeal epithelial cell lines NP69, NPC tissues and cell lines. EIF4G1 protein expression in NPC tissues was examined using immunohistochemistry. Survival analysis was performed using Kaplan-Meier method. The effect of EIF4G1 on cell invasion and tumorigenesis were investigated.
  
  
  RESULTS
  The expression levels of EIF4G1 mRNA were significantly greater in NPC tissues and cell lines than those in the normal nasopharyngeal tissues and NP69 cells (P < 0.001). Immunohistochemical analysis revealed that the expression of EIF4G1 protein was higher in NPC tissues than that in the nasopharyngeal tissues (P < 0.001). In addition, the levels of EIF4G1 protein in tumors were positively correlated with tumor T classification (P = 0.039), lymph node involvement (N classification, P = 0.008), and the clinical stages (P = 0.003) of NPC patients. Patients with higher EIF4G1 expression had shorter overall survival time (P = 0.019). Multivariate analysis showed that EIF4G1 expression was an independent prognostic indicator for the overall survival of NPC patients. Using shRNA to knock down the expression of EIF4G1 not only markedly inhibited cell cycle progression, proliferation, migration, invasion, and colony formation, but also dramatically suppressed in vivo xenograft tumor growth.
  
  
  CONCLUSIONS
  Our data suggest that EIF4G1 can serve as a biomarker for the prognosis of NPC patients.
authors.affiliation: Cancer Research Institute, Key Lab for Transcriptomics and Proteomics of Human Fatal Diseases, Ministry of Education and Guangdong Province, Southern Medical University, Guangdong Province, PR China.
authors.forename: Luxia
authors.initials: L
authors.lastname: Tu
authors.forename: Zhen
authors.initials: Z
authors.lastname: Liu
authors.forename: Xiufang
authors.initials: X
authors.lastname: He
authors.forename: Ying
authors.initials: Y
authors.lastname: He
authors.forename: Huiling
authors.initials: H
authors.lastname: Yang
authors.forename: Qingping
authors.initials: Q
authors.lastname: Jiang
authors.forename: Siming
authors.initials: S
authors.lastname: Xie
authors.forename: Guanghui
authors.initials: G
authors.lastname: Xiao
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Kaitai
authors.initials: K
authors.lastname: Yao
authors.forename: Weiyi
authors.initials: W
authors.lastname: Fang
mesh_terms: D000328:Adult; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D049109:Cell Proliferation; D002469:Cell Separation; D018450:Disease Progression; D039603:Eukaryotic Initiation Factor-4G / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015854:Up-Regulation; D023041:Xenograft Model Antitumor Assays
chemical_list: D014408:Biomarkers, Tumor; C113920:EIF4G1 protein, human; D039603:Eukaryotic Initiation Factor-4G
references.citation: Cancer Invest. 2004;22(4):483-91
references.pmid: 15565804
references.citation: J Radiat Res. 2007 May;48(3):211-8
references.pmid: 17464096
references.citation: Biol Cell. 2003 May-Jun;95(3-4):141-56
references.pmid: 12867079
references.citation: Biochem Biophys Res Commun. 2009 Jan 9;378(2):313-8
references.pmid: 19032949
references.citation: Nat Cell Biol. 2009 Jul;11(7):903-8
references.pmid: 19525934
references.citation: J Pathol. 2009 Sep;219(1):114-22
references.pmid: 19557828
references.citation: Cancer Res. 2009 May 15;69(10):4461-7
references.pmid: 19435892
references.citation: Oncogene. 2004 Apr 1;23(14):2484-98
references.pmid: 14676830
references.citation: Mol Cell. 2007 Nov 9;28(3):501-12
references.pmid: 17996713
references.citation: Mol Cell Biol. 2003 Jan;23(1):26-37
references.pmid: 12482958
references.citation: J Transl Med. 2008 Oct 04;6:55
references.pmid: 18834541
references.citation: Nat Med. 1997 Aug;3(8):917-21
references.pmid: 9256286
references.citation: Cancer Res. 1997 Nov 15;57(22):5041-4
references.pmid: 9371500
references.citation: J Cell Biol. 2002 Jul 8;158(1):165-74
references.pmid: 12105188
references.citation: Oncogene. 2006 Oct 16;25(48):6423-35
references.pmid: 17041627
references.citation: Clin Cancer Res. 2000 Oct;6(10):4064-8
references.pmid: 11051257
references.citation: Ai Zheng. 2002 Feb;21(2):158-62
references.pmid: 12479066
references.citation: Int J Cancer. 2002 Mar 10;98(2):181-5
references.pmid: 11857405
references.citation: Head Neck. 2008 Jul;30(7):946-63
references.pmid: 18446839
references.citation: RNA. 2005 Mar;11(3):261-74
references.pmid: 15661843
references.citation: Mol Cancer. 2007 Jan 02;6:1
references.pmid: 17199893
references.citation: Oncogene. 2003 Nov 13;22(51):8263-70
references.pmid: 14614450
references.citation: Mol Cancer. 2004 Dec 03;3(1):35
references.pmid: 15579197
references.citation: Cell. 2007 Jan 26;128(2):257-67
references.pmid: 17254965
references.citation: Nan Fang Yi Ke Da Xue Xue Bao. 2009 May;29(5):844-7, 851
references.pmid: 19460689
references.citation: J Transl Med. 2008 Jun 20;6:32
references.pmid: 18570662
references.citation: Int J Cancer. 2007 Jun 15;120(12):2538-44
references.pmid: 17290396
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3960-7
references.pmid: 17606730
references.citation: Mol Cancer. 2009 Sep 03;8:70
references.pmid: 19728867
references.citation: J Exp Clin Cancer Res. 2009 May 29;28:71
references.pmid: 19480673
references.citation: EMBO J. 2003 Apr 15;22(8):1909-21
references.pmid: 12682023